| Project/Area Number |
18K09128
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56030:Urology-related
|
|---|
| Research Institution | Jichi Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
高山 賢一 地方独立行政法人東京都健康長寿医療センター(東京都健康長寿医療センター研究所), 東京都健康長寿医療センター研究所, 専門副部長 (50508075)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | 前立腺癌 / プレシジョンメディシン / アンドロゲン / エストロゲン / 分子診断 / TRIM36 |
|---|
| Outline of Final Research Achievements |
Androgen deprivation therapy (ADT) for prostate cancer aims to control the action of androgen receptors (ARs) involved in the growth of cancer cells. In some cases, long-term survival is achieved with this ADT, and in other cases, castration resistant prostate cancer (CRPC) develops relatively early, leading to cancer death. This study created a nomogram that predicts cancer-specific survival of metastatic prostate cancer cases using paraffin specimens of prostate needle biopsy by a simple method, and is expected to develop into precision medicine.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究にて診断時のパラフィン標本から比較的簡易にADTの耐久性を診断することができた。ADTの治療効果が低い症例は初期にタキサン系抗癌剤、免疫チェックポイント阻害薬や新規の治療薬の候補となりえる。今後は独立したコホートでの検証や、商用化に向けた妥当性の検討が必要である。
|
